drugset / Trial / NCT01427582
YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access
Expanded access
No longer available
University of Texas Southwestern Medical Center
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · collab
Summary
The YONDELIS (trabectedin) Single Patient Compassionate Use /Expanded Access program provides patients with advanced soft tissue sarcoma, who do not qualify for ongoing clinical trials with YONDELIS (trabectedin), access to this investigational treatment.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trabectedin | Small molecule | 1.5 mg/m2 | Intravenous |